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a  b  s  t  r  a  c  t
Seven  studies  were  conducted  in  commercial  grazing  operations  to  conﬁrm  anthelmintic
efﬁcacy,  assess  acceptability,  and  measure  the  productivity  response  of  cattle  to treatment
with eprinomectin  in  an  extended-release  injectable  formulation  (ERI)  when  exposed  to
nematode  infected  pastures  for  120  days.  The  studies  were  conducted  under  one protocol
in the  USA  in  seven  locations  (Arkansas,  Idaho,  Louisiana,  Minnesota,  Missouri,  Oregon,  and
Wisconsin). Each  study  had  67–68  naturally  infected  animals  for  a total  of  475  (226  female,
249  male  castrate)  Angus  or beef-cross  cattle.  The  animals  weighed  133–335  kg  prior  to
treatment  and  were  approximately  3–12  months  of age. The  studies  were  conducted  under
a randomized  block  design  based  on pre-treatment  body  weights  to  sequentially  form  17
replicates of  four  animals  each  within  sex  in  each  study.  Animals  within  a  replicate  were
randomly  assigned  to treatments,  one  to Eprinomectin  ERI  vehicle  (control)  and  three  to
Eprinomectin  ERI (5%,  w/v eprinomectin).  Treatments  were  administered  at  1  mL/50  kg
body weight  once  subcutaneously  anterior  to the shoulder.  All  animals  in  each  study  grazed
one pasture  throughout  the  observation  period  of  120  days.  Cattle  were  weighed  and  fecal
samples collected  pre-treatment  and  on 28, 56, 84,  and  120  days  after  treatment  for fecal
egg and  lungworm  larval  counts.  Positive  fecal  samples  generally  were  cultured  en  masse
to determine  the nematode  genera  attributable  to  the  gastrointestinal  helminth  infection.
Bunostomum,  Cooperia,  Haemonchus,  Nematodirus,  Oesophagostomum,  Ostertagia,  and  Tri-
chostrongylus, when  present,  were  referred  to  as  strongylids.  At all  post-treatment  sampling
intervals, Eprinomectin  ERI-treated  cattle had  signiﬁcantly  (P  < 0.05)  lower  strongylid  egg
counts than  vehicle-treated  controls,  with  ≥95%  reduction  after  120  days  of  grazing.  Over
this same  period,  Eprinomectin  ERI-treated  cattle  gained  more  weight  (43.9  lb/head)  than
vehicle-treated  controls  in all studies.  This  weight  gain  advantage  was  signiﬁcant  (P  < 0.05)
in six of  the  studies  with  the Eprinomectin  ERI-treated  cattle  gaining  an  average  of  42.8%  and
the control  cattle  gaining  
in the  treated  animals.
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1. Introduction
The overall impact of internal parasitism in grazing cat-
tle is assessed by productivity, which can be measured as
weight gain, feed conversion, carcass composition or qual-
ity, reproductive performance or milk production. Whether
the level of infection observed is clinical or subclinical, pro-
ductivity losses can be the result of many factors working
in synergy. Decreased feed intake, impaired nutrient uti-
lization, and alterations in metabolism and immune status
are factors associated with parasitism that can affect pro-
ductivity. The effect on the parasitized cattle and the loss
of productivity are not only evident during the ﬁrst grazing
season, but may  also affect the productivity of those ani-
mals for the second and subsequent seasons (Holste et al.,
1986; Hawkins, 1993; Forbes et al., 2004; Sutherland and
Scott, 2010).
Preventive and therapeutic anthelmintic programs
involving scheduled dosing, formulations with prolonged
duration of activity, and sustained release devices have
been developed. The goal of these programs was to remove
an established parasite infection and prevent re-infection,
reduce pasture contamination early in the grazing season,
and maintain low numbers of infective larvae on the pas-
ture for the duration of the season. An additional beneﬁt of
formulations with prolonged activity or sustained release
is the reduction in frequency of animal handling resulting
in reduced animal stress and labor costs.
Eprinomectin is a macrocyclic lactone belonging to
the second generation avermectin group of endectocides
for cattle. Eprinomectin in a 0.5% pour-on formula-
tion at 0.5 mg/kg body weight has been shown to
be highly efﬁcacious against adult and immature gas-
trointestinal nematodes (Shoop et al., 1996; Gogolewski
et al., 1997a,b; Pitt et al., 1997; Williams et al., 1997;
Yazwinski et al., 1997; Batty et al., 1999; Epe et al.,
1999; Cramer et al., 2000; Dorny et al., 2000; Höglund
et al., 2003). Subsequently, an extended-release injectable
(ERI) formulation of eprinomectin has been developed
for the therapeutic and persistent control of nematode
infections in cattle (Soll et al., 2013; Rehbein et al.,
2013). The ERI formulation incorporates eprinomectin
into poly(d,l-lactide-co-glycolic)acid (PGLA), which forms
an extended-release biodegradable drug delivery matrix
when injected subcutaneously.
The objective of these studies was to conﬁrm 120-
day persistent efﬁcacy, acceptability, and productivity
response to eprinomectin extended-release injection solu-
tion when administered subcutaneously at 1 mg/kg body
weight in a single injection to beef cattle in commercial
grazing operations.
2. Materials and methods
The studies were conducted under one protocol in the
USA at seven locations (Arkansas, Idaho, Louisiana, Min-
nesota, Missouri, Oregon and Wisconsin). Study personnel
involved in collecting post-treatment data were blinded to
treatment assignments for the study duration. The studies
were designed and conducted to comply with the regula-
tory requirements of both the FDA/CVM and the Europeantology 192 (2013) 332– 337 333
Medicines Agency/Committee for Medicinal Products for
Veterinary Use, and according to relevant guidelines for
Good Clinical Practices (GCPs) and for establishing the efﬁ-
cacy of cattle anthelmintics.
2.1. Experimental animals
A total of 475 (226 female, 249 male-castrate) Angus
or beef-cross cattle, weighing approximately 133–335 kg
prior to treatment (Day −5 to Day 0), and aged approxi-
mately 3–12 months were utilized in seven studies (67–68
animals per study) in a variety of locations in the USA.
The animals had not been treated previously with an aver-
mectin or milbemycin product. Animal descriptions and
details are provided in Table 1. All cattle were exposed to a
natural parasitic infection by grazing for several weeks on
pasture contaminated by cattle nematodes prior to treat-
ment. In one study the cattle were held in a dry lot for 30
days prior to treatment. Nematode parasite infections were
conﬁrmed on the basis of positive fecal examinations prior
to treatment.
2.2. Experimental design
All studies were conducted using a randomized block
design based on pre-treatment bodyweight. Seventeen
replicates of 4 cattle each were formed sequentially, within
sex, based on pre-treatment (Day −5 to Day 0) body-
weights. Within replicates each animal was randomly
allocated to treatment: one to the Eprinomectin ERI vehicle
(control) group at 1 mL/50 kg bodyweight and three to the
Eprinomectin 5% (w/v) ERI group at 1 mL/50 kg bodyweight
(1.0 mg  eprinomectin/kg). This allocation scheme resulted
in a total of 17 controls and 51 treated in each study, except
for a single replicate in the Idaho study which consisted
of only three animals (one control and two treated), 50
Eprinomectin ERI-treated total.
Treatments were administered at 1 mL/50 kg body-
weight once on Day 0 by subcutaneous injection in front
of the shoulder using individual sterile syringes and nee-
dles. Dose volumes were rounded to the next 1 mL  above
the calculated dose volume if the bodyweight was between
the 50 kg increments.
Fecal samples were collected pre-treatment (between
Day −7 and 0) and on Days 28, 56, 84, and 120
from all the animals for fecal egg (quantitative ﬂota-
tion techniques) and lungworm larval (Baermann tech-
nique) counts. Fecal egg count methods involved single
centrifugation–ﬂotation procedures with sodium chlo-
ride as the ﬂotation medium in Idaho and Oregon
and with magnesium sulfate in Arkansas. A double
centrifugation–ﬂotation with sucrose was conducted in
Louisiana, Minnesota, Missouri, and Wisconsin. The sen-
sitivities of the methods in eggs per gram were as follows:
0.2 in Idaho, Oregon and Wisconsin; 0.3 in Louisiana; 0.5
in Minnesota; 2.0 in Arkansas and 0.2/0.5 in Missouri. A
coproculture procedure using the Baermann technique for
larval recovery was employed for the identiﬁcation of the
larvae of gastrointestinal nematodes. In general, positive
fecal samples were cultured en masse to determine nema-
tode composition by genera. Samples of fecal composites
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Table 1
Animal description and details.
Study site Treatmenta/animals
per treatment
Breed Sexb ∼Age (months) Pre-treatment bodyweight (kg)c
Louisianad (late
Feb–late Jun)
Control n = 17
EpERI n = 51
Angus cross 60 MC, 8 F 10–12 207.7–299
Arkansasd (late
Apr–late Aug)
Control n = 17
EpERI n = 51
Beef cross 8 MC, 60 F 4–6 147.4–208.7
Idahod (early
May–early Sep)
Control n = 17
EpERI n = 50e
Mixed beef cross 67 MC 8–12 196.9–334.8
Missouri (early
Apr–early Aug)
Control n = 17
EpERI n = 51
Angus, Angus cross 34 MC,  34 F 6–7 133–239
Minnesotad (early
Jun–early Oct)
Control n = 17
EpERI n = 51
Angus cross 68 MC 3–12 141.1–267.2
Wisconsind (early
May–early Sep)
Control n = 17
EpERI n = 51
Beef cross 68 F 6–8 162.8–273.5
Oregond (late
Mar–late Jul)
Control n = 17
EpERI n = 51
Mixed beef 12 MC,  56 F 4–8 143.3–283.5
a Control, vehicle-treated; EpERI, Eprinomectin ERI.
b MC,  male castrate, F, female.
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pc Body weights were measured either on study Days −5, −4, −3, −1 or
d Animals weighed in lb. Weight converted to kg = weight in lb/2.2046.
e One replicate of the EpERI group consisted of two  instead of three ani
ere mixed with ground corncobs and activated charcoal
Arkansas), vermiculite (Louisiana, Idaho, Minnesota Mis-
ouri, and Oregon) or no diluent (Wisconsin). The samples
ere incubated for 7–14 days after which the larvae were
ollected by Baermann technique and identiﬁed to genus.
aermann techniques were used to examine fecal samples
or lungworm (Dictyocaulus viviparus) with sensitivities
anging from one larva in 50 g (Missouri) to one larva in
0 g (all remaining sites).
Cattle were weighed prior to treatment (from Day −5 to
ay 0) for allocation and dose calculation and on Days 28,
6, 84, and 120.
All animals were observed approximately hourly for
he ﬁrst 4 h after treatment. Thereafter, the animals were
bserved at least daily for health problems.
.3. Statistical methods
Eggs of nematode genera including Bunostomum,
ooperia, Haemonchus, Nematodirus, Oesophagostomum,
stertagia,  and Trichostrongylus, when present, were
eferred to as strongylids, and egg counts were reported
s eggs per gram.
Individual, fecal egg counts for each type of egg and
t each time point were transformed to the natural loga-
ithm of (count + 1) for calculation of geometric means. The
ercent efﬁcacy of Eprinomectin ERI compared to vehicle-
reated controls was calculated using the percent reduction
n egg counts at each time point as follows:
% Efﬁcacy = [C − T/C] × 100, where C is the geometric
ean of the vehicle (control) group and T is the geomet-
ic mean of the Eprinomectin ERI-treated group. Treatment
roups were compared using the Wilcoxon rank sum test.
 two-sided test was used at  ˛ = 0.05.
Egg count reductions for non-strongylid genera (e.g.,trongyloides, Capillaria, and Trichuris) or D. viviparus
ere not calculated whenever fewer than 40% of the
ehicle (control)-treated animals were infected at any
ost-treatment time point. treatment.
 that the total number of animals in the treatment group was 50.
Pre-treatment bodyweight and weight gain at study end
(Day 120) were analyzed using analysis of variance for a
randomized block design.
3. Results
Geometric mean egg counts prior to treatment were
low and were not signiﬁcantly different between treatment
groups at the individual sites. Egg counts remained low in
the vehicle-treated controls for the duration of the study at
the majority of study sites.
For all post-treatment time points, Eprinomectin ERI-
treated cattle had signiﬁcantly (P < 0.05) lower strongylid
egg counts than the vehicle-treated groups at all study sites.
Efﬁcacy was ≥91% at all post-treatment time points in six
of the seven studies. In one study (Missouri) an efﬁcacy of
88% was observed on Day 56, but ranged from 96% to 99%
at all other post-treatment time points. The summary of
strongylid egg count data is shown in Table 2.
As revealed by coproculture or fecal ﬂotation, gastroin-
testinal nematode genera Cooperia, Oesophagostomum,
Ostertagia and Trichostrongylus were present in the ani-
mals at all sites, Nematodirus at six sites, Haemonchus and
Strongyloides at ﬁve sites, Bunostomum and Capillaria at four
sites, and Trichuris at three sites.
Strongyloides, Capillaria,  and/or Trichuris spp. eggs and
Dictyocaulus larvae were found in some animals of some
studies; however, numbers of control animals shedding
these eggs and/or larvae post-treatment were insufﬁcient
to permit a meaningful analysis of drug efﬁcacy. Dicty-
ocaulus viviparus larvae were infrequently observed in fecal
examinations before treatment in ﬁve studies (Arkansas,
Louisiana, Missouri, Oregon, and Wisconsin), but were
not detected in any Eprinomectin ERI-treated animal post
treatment.Pre-treatment bodyweights were not signiﬁcantly
different between the Eprinomectin ERI-treated and
vehicle-treated (control) cattle in any of the studies. Weight
gain to Day 120 was  signiﬁcantly (P < 0.05) higher for
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Table 2
Summary of strongylid egg count data and efﬁcacy.
Study site Treatmentc Strongylid eggs per gram counts (GMd)
Efﬁcacye
Days before treatment Days after treatment
−7 to −3 0 28 56 84 120
Louisiana Control 281 (0.99) [40.0–900.0] 140 (1.09) [13.0–920.0] 28 (1.74) [1.0–490.0] 22 (1.60) [3.0–810.0] 14 (1.19) [2.0–233.0] 19 (1.13) [1.7–117.0]
EpERI 148 (1.25) [1.0–885.0] 82a (1.44) [1.3–1033.3] <1b ((1.62) [0.0–65.3] <1b ((0.90) [0.0–67.0] <1b ((0.17) [0.0–2.0] <1b ((0.35) [0.0–9.0]
Efﬁcacy –  – 98% 98% >99% >99%
Arkansas Control 60 (1.04) [6–290] 79 (1.09) [12–598] 61 (1.08) [4–224] 191 (1.87) [2–1374] 359 (1.29) [36–3240] 220 (1.52) [10–2278]
EpERI  68 (0.95) [6–402] 65a (1.05) [4–792] <1b ((0.84) [0–18] 1b ((0.90) [0–20] 2b ((1.03) [0–46] 3b ((1.26) [0–518]
Efﬁcacy  – – 99% >99% >99% 98%
Idaho Control 75 (0.99) [20–620] 59 (0.84) [10–240] 19 (1.54) [0–110] 14 (1.66) [0–80] 11 (1.28) [0–50] 2 (1.40) [0–30]
EpERI  76 (1.19) [10–1310] 61a (1.22) [10–1200] 0b ((0.34) [0–10] 0b ((0.34) [0–10] 0b (0) 0b (0)
Efﬁcacy – – >99% >99% 100% 100%
Missouri Control 51 (1.09) [4.4–236.2] 96 (1.02) [10.0–472.5] 42 (1.28) [3.6–320.6] 18 (0.87) [1.4–115.8] 34 (1.15) [1.4–209.8] 21 (1.43) [0.2–104.2]
EpERI 77 (1.24) [3.4–509.8] 112a (1.09) [2.5–597.0] 2b ((0.91) [0.0–27.6] 2b (1.01) [0.0–26.0 <1b ((0.21) [0.0–1.6] <1b ((0.46) [0.0–3.6]
Efﬁcacy  – – 96% 88% >99% 99%
Minnesota Control 28 (0.89) [7.5–132.5] 54 (0.52) [25–140.5] 12 (1.42) [0.0–148.5] 11 (1.21) [1.0–90.5] 8 (1.14) [0.0–44.0] 8 (0.94) [0.0–56.0]
EpERI 27 (1.03) [0.5–133] 23b (0.98) [2.0–166.5] <1b ((0.67) [0.0–12.0] <1b ((0.97) [0.0–104.5] <1b ((0.46) [0.0–14.0] <1b ((0.26) [0.0–3.0]
Efﬁcacy  – – 96% 93% 99% 99%
Wisconsin Control 27 (0.10) [0.2–96.0] NAf 6 (1.32) [0.0–50.4] 3 (1.38) [0.0–52.8] 6 (1.22) [0.0–86.4] 4 (1.12) [0.0–35.6]
EpERI 27 (0.72) [7.2–237.6] NA <1b ((0.44) [0.0–8.6] <1b ((0.38 [0.0–8.0] <1b ((0.24) [0.0–2.6] 0b ((0.12) [0.0–1.2]
Efﬁcacy  – – 97% 94% 99% >99%
Oregon Control 51 (1.18) [10–480] 59 (1.37) [10–1170] 84 (1.56) [0–760] 58 (1.84) [0–590] 19 (2.12) [0–380] 17 (1.40) [0–190]
EpERI  35 (1.10) [10–920] 44a (1.10) [10–750] 3b ((1.82) [0–290] 4b ((2.10) [0–440] 2b ((1.63) [0–200] 1b ((1.24) [0–60]
Efﬁcacy – – 96% 94% 91% 95%
() = standard deviation.
[] = range.
a Probability from Wilcoxon rank sum test: not signiﬁcant at ˛ = 0.05.
b Probability from Wilcoxon rank sum test: P < 0.05.
c Control, vehicle-treated; EpERI, Eprinomectin ERI.
d Geometric mean strongylid egg counts (based on transformation to the natural logarithm of [count + 1]).
e Efﬁcacy = 100 [(geometric mean control − geometric mean Eprinomectin ERI)/geometric mean control].
f NA, not applicable because fecal samples were not evaluated.
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Table 3
Summary of body weight and weight gain data.
Study site Treatment Meanb pre-treatment body weight (kg)a
Probabilityc
Weight gain (kg) to study Day 120b
Probabilityc
Louisianad Controle 253.7 91.9 [36.2%]
Eprinomectin ERI 253.2 122.3 [48.3%]
P  = 0.77 P < 0.05
Arkansasd Control 168.8 38.0 [22.5%]
Eprinomectin ERI 169.4 57.1 [33.7%]
P = 0.59 P < 0.05
Idahod Control 264.4 69.5 [26.3%]
Eprinomectin ERI 264.4 78.1 [29.5%]
P = 0.98 P = 0.16
Missouri Control 182.1 48.5 [26.6%]
Eprinomectin ERI 182.2 72.1 [39.6%]
P = 0.98 P < 0.05
Minnesotad Control 215.8 73.4 [34.0%]
Eprinomectin ERI 214.1 79.9 [37.3%]
P = 0.11 P < 0.05
Wisconsind Control 221.8 90.2 [40.7%]
Eprinomectin ERI 221.9 112.2 [50.6%]
P  = 0.85 P < 0.05
Oregond Control 201.2 91.8 [45.6%]
Eprinomectin ERI 199.9 121.1 [60.6%]
P  = 0.60 P < 0.05
a Body weights were measured either on study Days −5, −4, −3, −1 or 0 before treatment.
b Least squares means rounded to one degree of precision post-calculation.
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e Control, vehicle-treated.
nimals treated with Eprinomectin ERI than it was for
ehicle-treated (control) animals in six studies as shown
n Table 3.
No drug-related health problems or adverse drug events
ere observed at any time during the studies.
. Discussion
The primary objective of these studies was to assess
he therapeutic and prophylactic efﬁcacy of Eprinomectin
RI under continuous exposure to infective larvae and/or
ggs under ﬁeld use conditions. The pre- and recurrent
ost-treatment fecal egg counts and coprocultures sub-
tantiate that the animals were infected pre-treatment and
hat continuous pasture contamination and animal expo-
ure occurred throughout the 120-day grazing periods. The
egree of challenge/exposure varied over time, but in gen-
ral was the highest in Arkansas and Louisiana, slightly less
n Oregon, Missouri, and Idaho, and lowest in Minnesota
nd Wisconsin. These ﬁndings are consistent with those of
rior studies (Rew and Vercruysse, 2002; Cleale et al.,  2004;
ildreth et al., 2007; Rehbein et al., 2013), and are represen-
ative of geographic locations of the United States where
arasitic infections in cattle are usually subclinical. The
iversity of nematode challenge was demonstrated by the
oproculture results across all study locations. Cooperia and
stertagia were the two genera found most consistently
t all study sites pre- and post-treatment. Oesophagosto-
um, Trichostrongylus, Nematodirus, and Haemonchus were
he next most commonly found genera in most of the
tudy locations. Bunostomum was the genus observed in
he fewest number of study locations.alues rounded to two  degrees of precision.
The anthelmintic efﬁcacy of Eprinomectin ERI, both
therapeutically and prophylactically, was  evident at all
study locations. Reduction of strongylid egg counts in the
Eprinomectin ERI-treated animals was signiﬁcantly greater
(P < 0.05) when compared to the vehicle-treated controls
at Day 28 (≥96%) and throughout the grazing period. Egg
count reduction was  still ≥ 95% at the termination of the
studies on Day 120. The reduced fecal output of strongylid
eggs would result in reduced larval pasture contamina-
tion, as observed elsewhere (Stromberg and Averbeck,
1999).
The pre-treatment body weights were not signiﬁcantly
different between treatments at any trial site location. Over
the course of the 120-day grazing period, the Eprinomectin
ERI-treated cattle gained more weight (43.9 lb/head) than
the vehicle-treated controls in all studies. The difference
in the 120-day weight gain was  signiﬁcant (P < 0.05) in
six of the studies with the Eprinomectin ERI-treated cattle
gaining an average of 42.8% and the control cattle gaining
33.1% of their initial weight. Differences in growth between
nematode-infected cattle and anthelmintic-treated cat-
tle were comparable to estimates noted in other studies
(Rickard et al., 1991; Jacobsen et al., 1996; Ryan et al.,
1997; Forbes et al., 2002; Mertz et al., 2005; Rehbein et al.,
2013). These reports conﬁrm that signiﬁcant productiv-
ity beneﬁts from anthelmintic treatment can be observed
even when fecal egg counts are relatively low. It should
be noted that treated and control cattle grazed common
pastures in all the studies reported here. Thus untreated
cattle provide a continuous source of pasture contamina-
tion which would not be expected to occur if all cattle
were treated. Efﬁcacy and productivity results could there-
fore be expected to be greater if all co-grazing cattle were
treated.
y ParasiB.N. Kunkle et al. / Veterinar
Generally, the mean fecal egg counts of the controls
were low at the beginning of the trial and gradually
decreased over the 120-day duration of the studies. This
possibly was due to climatic conditions and/or increasing
immunity. In spite of low and decreasing fecal egg counts in
the controls, signiﬁcant (P < 0.05) efﬁcacy ranging from 91
to 100% was observed at all time points with the exception
of Day 56 in the Missouri study.
In conclusion, the results of these ﬁeld studies
demonstrate that eprinomectin in an extended-release
formulation can safely and effectively treat and prevent
nematode endoparasite infections and increase productiv-
ity while requiring fewer treatments during the grazing
season.
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